Maxim Group analyst Jason McCarthy downgrades Kintara Therapeutics (NASDAQ:KTRA) from Buy to Hold.
KBR’s Backlog Jumps 10% In FY23, Dividend Raised By 11%
KBR delivered a 10% increase in backlog and options in 2023. The company's Board approved an increase of quarterly regular dividend and authorized replenishment of its share repurchase authorization to $500 million.
